IgM monoclonal antibodies targeting peptidoglycan

IgM monoclonal antibodies targeting peptidoglycan (PGN) represent a novel class of immunotherapies designed to treat and prevent antimicrobial-resistant (AMR) bacterial infections and sepsis. Peptidoglycan is a highly conserved structural component of the cell wall present in virtually all bacterial pathogens, including Gram-positive, Gram-negative, and mycobacterial species. By targeting PGN, these antibodies can recognize a broad spectrum of bacteria. The IgM isotype is particularly effective for acute infections due to its pentameric structure, which allows for high-avidity binding, potent activation of the complement cascade, and enhanced opsonophagocytic killing (OPK) of pathogens. Longhorn Vaccines and Diagnostics is developing candidates in this class, including DRG5-BD11, a bispecific human IgM monoclonal antibody targeting both peptidoglycan and the Mycobacterium tuberculosis heat shock protein HSP16.3.

Other names

anti-peptidoglycan IgM mAbsanti-peptidoglycan IgM monoclonal antibodiesanti-PGN IgM mAbsanti-PGN IgM monoclonal antibodies